Global Assets Advisory LLC Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Global Assets Advisory LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 9.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,808 shares of the company’s stock after buying an additional 670 shares during the period. Global Assets Advisory LLC’s holdings in Johnson & Johnson were worth $1,265,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Meridian Financial Partners LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at $1,626,000. Summit Financial Wealth Advisors LLC raised its position in Johnson & Johnson by 26.3% in the first quarter. Summit Financial Wealth Advisors LLC now owns 5,392 shares of the company’s stock valued at $853,000 after purchasing an additional 1,122 shares during the period. Franklin Parlapiano Turner & Welch LLC lifted its stake in shares of Johnson & Johnson by 0.7% during the first quarter. Franklin Parlapiano Turner & Welch LLC now owns 47,186 shares of the company’s stock worth $7,464,000 after purchasing an additional 325 shares in the last quarter. Capital Asset Advisory Services LLC grew its stake in shares of Johnson & Johnson by 8.8% in the first quarter. Capital Asset Advisory Services LLC now owns 26,539 shares of the company’s stock valued at $4,044,000 after buying an additional 2,151 shares in the last quarter. Finally, NTV Asset Management LLC lifted its position in Johnson & Johnson by 1.6% during the 1st quarter. NTV Asset Management LLC now owns 36,000 shares of the company’s stock worth $5,695,000 after acquiring an additional 565 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 1.3 %

NYSE JNJ opened at $163.67 on Friday. The firm has a market capitalization of $393.90 billion, a PE ratio of 10.20, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The company has a 50-day simple moving average of $163.29 and a 200-day simple moving average of $154.92. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same period in the prior year, the company earned $2.66 earnings per share. The business’s revenue was up 5.2% compared to the same quarter last year. On average, equities analysts forecast that Johnson & Johnson will post 10 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.03%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on JNJ shares. Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. TD Securities dropped their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Royal Bank of Canada raised their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Finally, TD Cowen dropped their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. Six equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.93.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.